阿尔茨海默病的非典型表现
概括
本综述详细介绍了四种非典型的阿尔茨海默病 (AD) 变体,强调它们独特的非记忆症状,脑成像发现,以及为更好的患者管理量身定制的治疗需求.
科学领域:
- 神经学 神经学
- 神经科学是一个神经科学.
- 老年病的医生 老年病的医生
背景情况:
- 非典型的阿尔茨海默氏病 (AD) 变体存在与非记忆相关的症状,与典型的AD不同.
- 四个关键的变体包括dysexecutive AD,行为变体AD,后皮层缩,以及初级渐进性失语症的logopenic变体.
研究的目的:
- 综合审查四种非典型阿尔茨海默病 (AD) 变体的独特特征.
- 阐明它们的临床表现,病理生理路径,诊断指标和管理要求.
主要方法:
- 关于非典型阿尔茨海默氏症变异的当前研究的综述.
- 分析神经成像技术,包括MRI,FDG-PET和tau PET.
- 对用于诊断和区分的生物标志物分析的检查.
主要成果:
- 非典型的AD变体表现出不同的临床表现和功能神经解剖学.
- 神经成像显示每个变体的特定区域大脑异常,与粉样蛋白成像相关性较小.
- 现在已公认的实体是 Dysexecutive AD 和行为变体 AD,取代了旧的术语.
结论:
- 不典型的AD变体的准确诊断依赖于像MRI和PET这样的现代技术.
- 量身定制的治疗策略,结合药物治疗和非药物治疗方法,对于有效的管理至关重要.
- 了解变体特异性特征对于推进AD的诊断和治疗方法至关重要.
相关概念视频
Alzheimer's Disease: Overview
447
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
447
Alzheimer's Disease: Treatment
163
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
163
Dementia
96
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
96
Parkinson's Disease: Overview
479
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
479
Amyloid Fibrils
9.2K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.2K
Parkinson's Disease: Treatment
219
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
219


